ReviewMediators of inflammation2013
Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.
Review in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in medicine · 2019Pooled it
- Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.The Cochrane database of systematic reviews · 2018Pooled it
- Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.Arthritis care & research · 2016Trial
- In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis.BioMed research international · 2015Trial
- Disproportionality analysis highlights paradoxical psoriasis as a clinically significant class effect of tumor necrosis-α inhibitors in pediatric populations.Pediatric research · 2026Article
- Shaping the Future of Behçet's Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies.Ophthalmology and therapy · 2023Review
- The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era.Rheumatology international · 2022Review
- Effects of anti-TNF biologic drugs on uveitis severity in Behçet patients: systematic review and Meta-analysis.International journal of ophthalmology · 2022Article
- Review
- [Scar sarcoidosis: a usually progressive disease (about a case)].The Pan African medical journal · 2021Article
- [Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020Article
- Chitosan Oligosaccharides Suppress Nuclear Factor-Kappa B Activation and Ameliorate Experimental Autoimmune Uveoretinitis in Mice.International journal of molecular sciences · 2020Article
- Review
- Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study.Frontiers in immunology · 2020Article
- Article
- An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Orphanet journal of rare diseases · 2017Review
- CNS Demyelination with TNF-α Blockers.Current neurology and neuroscience reports · 2017Review
- Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2017Article
- Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.Turkish journal of ophthalmology · 2016Review
- Successful treatment with infliximab for refractory para-ileostomal ulceration in a patient with Behҫet's disease.Clinical journal of gastroenterology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet's disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.